Episode Summary
Executive Summary: The episode examines ibogaine, a psychedelic derived from an African plant that is being promoted for opioid addiction, PTSD, and other mental health conditions. Personal stories and observational studies suggest dramatic short-term benefits, but the drug can also trigger dangerous heart arrhythmias and there is no placebo-controlled evidence showing durable benefit without serious risk. The show concludes that ibogaine remains promising but experimental, expensive, and too risky for casual or unsupervised use.
Main Topics: What ibogaine is and why it’s in the headlines (Priority: 5/5): The hosts introduce ibogaine as a newly prominent psychedelic, discuss political enthusiasm around it, and explain that it comes from the iboga plant used in West African indigenous medicine. Personal addiction-recovery stories (Priority: 5/5): Retz Chapman and Holly describe severe opioid addiction, intense ibogaine trips, and major short-term reductions in cravings, withdrawal, shame, and trauma-related distress. Mechanism and neuroplasticity hypotheses (Priority: 4/5): Scientists do not fully understand how ibogaine produces its hallucinations, but animal and limited human data suggest it may increase neuroplasticity and help rewire addiction-related brain circuits. Evidence for addiction treatment (Priority: 5/5): Several observational studies, including Alan Davis’s survey work, found large self-reported reductions in withdrawal and craving, but these studies lacked placebo controls and may be biased. Safety risks and cardiac toxicity (Priority: 5/5): Ibogaine can interact dangerously with heart potassium channels, causing arrhythmias and potential death; this risk halted an NIH trial and is the major barrier to approval. Placebo-controlled trial and lack of efficacy at safe doses (Priority: 5/5): A randomized trial of noribogaine (a related compound) found no benefit over placebo for opioid withdrawal at doses low enough to avoid serious cardiac harm. Clinical caution and comparison to other psychedelics (Priority: 4/5): Researchers advise that if someone wants psychedelic treatment, regulated psilocybin therapy is currently better studied and safer than traveling for ibogaine treatment.
Key Arguments: Ibogaine can produce dramatic subjective and behavioral changes, especially around withdrawal and trauma, but much of the evidence comes from uncontrolled or observational studies. The best available self-report studies suggest many people feel immediate relief from opioid withdrawal and cravings after ibogaine, with some maintaining abstinence for long periods. However, the strongest controlled evidence shows that safer doses of related compounds do not improve withdrawal, while ibogaine itself carries real cardiac danger. The long duration of the trip may be part of why ibogaine seems to help, possibly by creating a large neuroplasticity window for psychological change. Some reported benefits may be confounded by additional treatments, including DMT given soon after ibogaine in some clinics. Because people with severe addiction may already face high mortality risk, some individuals may judge the danger differently, but the therapy should still be approached cautiously and medically supervised.
Data Points: Estimated people worldwide with opioid addiction: 16 million - The episode cites global opioid addiction burden as part of the rationale for studying ibogaine. People surveyed in Alan Davis’s study: 88 - Survey respondents from an ibogaine clinic in Mexico used to assess self-reported outcomes. People originally contacted in that study: 285 - Only 88 responded, raising selection bias concerns. Reported reduction in detox symptoms/craving: 80% - Alan Davis reported that 80% of respondents said withdrawal/craving improved greatly or disappeared after ibogaine. Long-term abstinence rate: 30% - In Alan Davis’s follow-up, about 30% of the full group remained completely abstinent from opioids up to two years later. Heart-risk trial participants: 27 - Placebo-controlled noribogaine trial conducted in hospitalized opioid-dependent participants. Documented deaths linked to ibogaine: 30-40 - Approximate total found across case reports over decades, including cases in the West and West Africa. Potential duration of intense phase: Up to 20 hours - The episode notes ibogaine’s most intense effects can last very long. Time to relive traumatic memories in personal accounts: During the trip - Retz and Holly described confronting buried trauma and abuse during the experience. Opioid overdose deaths in the U.S.: 55,000 per year - Used to contextualize why some severely addicted people may still take the risk. Clinic price for non-addiction/cognitive uses: $10,000-$20,000 - A clinic was described as marketing ibogaine for cognitive enhancement, clarity, and peace.
Pivotal Quotes: "it was almost like it was too good to be true" — Retz Chapman: His reaction to hearing claims that ibogaine could help addiction before trying it. "this is not going to be a magic bullet for people" — Alan Davis: His conclusion after finding short-term benefits but only 30% long-term abstinence. "you are officially dead" — Paul Glu: He was explaining the danger of ibogaine-induced arrhythmias when heart rhythm fails.
Implications: Ibogaine may help some people in the short term, but its cardiac risks, weak controlled evidence, and unclear durability make it unsuitable as a mainstream treatment yet. More rigorous, safer trials are needed before broad use.
About Science Vs
There are a lot of fads, blogs and strong opinions, but then there’s SCIENCE. Science Vs is the show from Spotify Studios that finds out what’s fact, what’s not, and what’s somewhere in between. We do the hard work of sifting through all the science so you don't have to and cover everything from 5G and ADHD, to Fluoride and Fasting Diets.